BR112021020709A2 - Métodos para administração de certos inibidores de vmat2 - Google Patents
Métodos para administração de certos inibidores de vmat2Info
- Publication number
- BR112021020709A2 BR112021020709A2 BR112021020709A BR112021020709A BR112021020709A2 BR 112021020709 A2 BR112021020709 A2 BR 112021020709A2 BR 112021020709 A BR112021020709 A BR 112021020709A BR 112021020709 A BR112021020709 A BR 112021020709A BR 112021020709 A2 BR112021020709 A2 BR 112021020709A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- administering certain
- vmat2 inhibitors
- administering
- certain vmat2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845599P | 2019-05-09 | 2019-05-09 | |
| PCT/US2020/032188 WO2020227672A1 (en) | 2019-05-09 | 2020-05-08 | Methods for the administration of certain vmat2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020709A2 true BR112021020709A2 (pt) | 2021-12-14 |
Family
ID=70919120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020709A BR112021020709A2 (pt) | 2019-05-09 | 2020-05-08 | Métodos para administração de certos inibidores de vmat2 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20200397779A1 (enExample) |
| EP (1) | EP3965764A1 (enExample) |
| JP (2) | JP2022531696A (enExample) |
| KR (1) | KR20220007105A (enExample) |
| CN (1) | CN114340624A (enExample) |
| AU (2) | AU2020270145A1 (enExample) |
| BR (1) | BR112021020709A2 (enExample) |
| CA (1) | CA3136466A1 (enExample) |
| EA (1) | EA202193012A1 (enExample) |
| IL (2) | IL321020A (enExample) |
| JO (1) | JOP20210274A1 (enExample) |
| MA (1) | MA55893A (enExample) |
| MX (1) | MX2021013132A (enExample) |
| PH (1) | PH12021552745A1 (enExample) |
| SG (1) | SG11202111465RA (enExample) |
| TW (1) | TWI850377B (enExample) |
| WO (1) | WO2020227672A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230170136A (ko) | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| IL309172A (en) * | 2021-06-30 | 2024-02-01 | Neurocrine Biosciences Inc | Vulbanazine for use in the additional treatment of schizophrenia |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
| CA3245030A1 (en) * | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE |
| TW202521119A (zh) * | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025038959A1 (en) * | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025188830A1 (en) * | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US952A (en) | 1838-09-27 | I antoni bengini | ||
| US10065A (en) | 1853-10-04 | Improvement in machines for topping cotton jn the field | ||
| FI3936130T3 (fi) * | 2014-05-06 | 2024-04-23 | Neurocrine Biosciences Inc | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon |
| US20190015396A1 (en) * | 2015-06-23 | 2019-01-17 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for treating neurological diseases or disorders |
| KR20230170136A (ko) * | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| SG11202100303QA (en) * | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
-
2020
- 2020-05-08 EA EA202193012A patent/EA202193012A1/ru unknown
- 2020-05-08 SG SG11202111465RA patent/SG11202111465RA/en unknown
- 2020-05-08 AU AU2020270145A patent/AU2020270145A1/en not_active Abandoned
- 2020-05-08 MX MX2021013132A patent/MX2021013132A/es unknown
- 2020-05-08 PH PH1/2021/552745A patent/PH12021552745A1/en unknown
- 2020-05-08 TW TW109115397A patent/TWI850377B/zh active
- 2020-05-08 CN CN202080034710.XA patent/CN114340624A/zh active Pending
- 2020-05-08 IL IL321020A patent/IL321020A/en unknown
- 2020-05-08 BR BR112021020709A patent/BR112021020709A2/pt unknown
- 2020-05-08 EP EP20729429.9A patent/EP3965764A1/en active Pending
- 2020-05-08 CA CA3136466A patent/CA3136466A1/en active Pending
- 2020-05-08 WO PCT/US2020/032188 patent/WO2020227672A1/en not_active Ceased
- 2020-05-08 MA MA055893A patent/MA55893A/fr unknown
- 2020-05-08 KR KR1020217039903A patent/KR20220007105A/ko not_active Ceased
- 2020-05-08 JP JP2021565932A patent/JP2022531696A/ja active Pending
- 2020-08-31 US US17/007,710 patent/US20200397779A1/en not_active Abandoned
-
2021
- 2021-10-11 JO JOP/2021/0274A patent/JOP20210274A1/ar unknown
- 2021-10-21 US US17/506,883 patent/US20220040169A1/en not_active Abandoned
- 2021-11-08 IL IL287902A patent/IL287902A/en unknown
-
2024
- 2024-10-24 JP JP2024187589A patent/JP2025013963A/ja active Pending
-
2025
- 2025-10-22 AU AU2025256123A patent/AU2025256123A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220007105A (ko) | 2022-01-18 |
| JP2025013963A (ja) | 2025-01-28 |
| MA55893A (fr) | 2022-03-16 |
| MX2021013132A (es) | 2021-11-25 |
| CA3136466A1 (en) | 2020-11-12 |
| EA202193012A1 (ru) | 2022-03-02 |
| TWI850377B (zh) | 2024-08-01 |
| JOP20210274A1 (ar) | 2023-01-30 |
| US20220040169A1 (en) | 2022-02-10 |
| AU2020270145A1 (en) | 2021-12-23 |
| SG11202111465RA (en) | 2021-11-29 |
| IL287902A (en) | 2022-01-01 |
| PH12021552745A1 (en) | 2022-07-11 |
| US20200397779A1 (en) | 2020-12-24 |
| EP3965764A1 (en) | 2022-03-16 |
| WO2020227672A1 (en) | 2020-11-12 |
| IL321020A (en) | 2025-07-01 |
| JP2022531696A (ja) | 2022-07-08 |
| AU2025256123A1 (en) | 2025-11-13 |
| TW202108138A (zh) | 2021-03-01 |
| CN114340624A (zh) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210274A1 (ar) | طرق لإعطاء مثبط vmat2 معين | |
| BR112022002834A2 (pt) | Métodos para a administração de certos inibidores de vmat2 a pacientes com insuficiência renal severa | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| BR112023025235A2 (pt) | Compostos de indol substituídos e métodos de uso dos mesmos | |
| AU2009303758A8 (en) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| BR112022019492A2 (pt) | Inibidores de rip1k | |
| MX2021003792A (es) | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. | |
| BR112017001010A2 (pt) | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais | |
| ECSP099525A (es) | Inhibidores de mek | |
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| BR112017003312A2 (pt) | compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
| BR112015005894A2 (pt) | composição farmacêutica | |
| BR112022025613A2 (pt) | Novo inibidor de secreção de ácido e uso do mesmo | |
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| BR112018015590A2 (pt) | modulação de receptor acoplado à proteína g (gpcr) por imipridonas | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| SG10201804026WA (en) | Inhibitors of influenza viruses replication | |
| MX2020008086A (es) | Metodos y composiciones para tratar la apnea del sue?o. | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| BR112018000786A2 (pt) | métodos e composições usando bifidobacterium longum para modular a reatividade emocional e tratar ou evitar perturbações subclínicas do estado de humor | |
| BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: NEUROCRINE BIOSCIENCES INC. (US) |